YONKERS, N.Y., October 3 /CNW/ - A new Phase II open label study at
McGill University will explore the effect of an investigational drug on
patients with recurrent or advanced cancer. Researchers indicate the treatment
may help patients who suffer from severe appetite loss, fatigue and weight
loss when undergoing aggressive cancer therapy.
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), a research
based biopharmaceutical company dedicated to anti-cancer drug discovery and
development, today announced the enrollment of the first patient into the
Phase II clinical trial.
The trial is being conducted at McGill University Health Centre (MUHC) in
Montreal, Quebec. Dr. Martin Chasen, a medical oncologist / palliative care
physician and Clinical Director of the McGill Cancer Nutrition and
Rehabilitation Program at McGill University, is the Principal Investigator.
The Phase II open label study will examine the effect of a 4.0 mL
subcutaneous dose of AVR118 on weight, appetite, performance status, and other
measures of quality of life in patients with recurrent or advanced
malignancies. AVR118 will be administered daily for a trial period of 28 days.
Patients who appear to benefit from the trial period dosing will be eligible
to continue on AVR118, generating longer term efficacy data.
According to Dr. Chasen, "AVR118 may offer a new treatment paradigm in
palliative care. Early identification and treatment of patients will hopefully
enable us to reduce the severely debilitating effects of cachexia and
Enrollment initially will include 14 patients between the ages of 18 and
85 who have recurrent or advanced malignancies and are suffering from symptoms
of cachexia, including muscle wasting, severe fatigue and loss of appetite.
Pending review of preliminary data, there is a provision to increase
enrollment to 30 patients.
"We are excited to have our first patient enrolled at McGill and hope to
improve the quality of life for all patients in this trial. Our company
remains committed to contributing to cancer symptom control and advancing
palliative care research," said Stephen M. Elliston, President and Chief
Executive Officer of ADVR.
Advanced Viral Research Corp. is a New York biopharmaceutical company
dedicated to improving patients' lives by researching, developing and bringing
to market new and effective therapies for the control of symptoms associated
with cancer and other serious diseases. Its initial compound AVR118 represents
a new class of cytoprotective agent that targets, among other things, cachexia
related disorders. Various degenerative conditions associated with body
wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are
potential disease targets for AVR118 therapy. AVR118 has also been shown to
have topical wound healing properties in animal models.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 is not
approved by the U.S. Food and Drug Administration or any comparable agencies
of any other countries. There is no assurance that the Company will be able to
secure the financing necessary to continue and/or complete the clinical trials
of AVR118 or satisfy certain other conditions relating to clinical trials
including obtaining adequate insurance on terms acceptable to the Company. The
Company undertakes no obligation to update or revise the information contained
in this announcement whether as a result of new information, future events or
circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please
visit the website at http://www.adviral.com.
For further information:
For further information: The Signature Agency Gayle Challinor,
800-870-8700 or 919-878-8989 or Advanced Viral Research Corp. Stephen M.
Elliston, 914-376-7383 Fax: 919-878-3939